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Abstract
Background: Macrophages expressing the pro-angiogenic transcription factor hypoxia-inducible factor (HIF)-1alpha
have been demonstrated in rheumatoid arthritis (RA) in the synovial tissue. Aim of the present study was to
investigate intracellular signal transduction regulation of pro-inflammatory HIF-1 alpha expression in macrophages
to identify possible new intervention strategies. We investigated the effects of CaMKII-inhibitors amongst other
kinase inhibitors, on HIF-1 alpha expression and downstream production of pro-angiogenic factors in macrophages.
Methods: Differentiated THP-1 cells and synovial fluid (SF) macrophages were stimulated with 1 μg/ml LPS with or
without pretreatment with specific inhibitors of the ERK pathway (PD98059), the PI3K pathway (LY294002), and the
CaMKII pathway (KN93 and SMP-114). mRNA and protein expression of HIF-1 alpha, VEGF, MMP-9, and IL-8 was
measured in cell lysates and cell supernatants.
Results: HIF-1 alpha protein expression in LPS-stimulated THP-1 macrophages could be blocked by ERK- and PI3K-
inhibitors, but also by the CaMKII inhibitor KN93. THP-1 and SF macrophages produced high levels of VEGF, IL-8,
and MMP-9, and VEGF protein production was significantly inhibited by PI3K-inhibitor, and by both CaMKII
inhibitors. LPS stimulation in an hypoxic environment did not change VEGF levels, suggesting that LPS induced
VEGF production in macrophages is more important than the hypoxic induction.
Conclusions: Expression of HIF-1 alpha and downstream effects in macrophages are regulated by ERK-, PI3K, but
also by CaMKII pathways. Inhibition of HIF-1a protein expression and significant inhibition of VEGF production in
macrophages was found using CaMKII inhibitors. This is an unknown but very interesting effect of the CaMKII
inhibitor SMP-114, which has been in clinical trial as DMARD for the treatment of RA. This effect may contribute to
the anti-arthritic effects of SMP-114.
Background
Macrophages are known to play an important role in
inflammatory diseases such as rheumatoid arthritis (RA),
as the rheumatoid synovium is intensively infiltrated by
macrophages and their numbers correlate well with
articular destruction [1] and clinical scores [2]. It has
long been recognized that synovial fluids from RA
patients are hypoxic, acidotic and have low glucose and
high lactate levels [3]. This is indicative of an anaerobe
situation, which has been confirmed by measuring
oxygen levels in the synovium. [4]. A microenvironment
of hypoxia leads to the formation of an ubiquitously
expressed transcription factor, hypoxia-inducible factor
(HIF-1), which regulates the expression of genes that
allows cells to use anaerobic metabolism to generate
energy for survival and secondly, to promote angiogen-
esis for oxygen supply [5]. The heterodimeric transcrip-
tion factor HIF is composed of two basic helix-loop-helix
(bHLH) proteins (HIF-1a and HIF-1b). The HIFa/b
dimer binds to a core DNA motif in the hypoxia respon-
sive elements, which are associated with a broad range of
target genes, such as vascular endothelial growth factor
(VEGF), erythropoietin (EPO), and glucose-transporter-1
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growth and migration, and a switch to a glytolytic cell
metabolism [6]. HIF-1b,a l s ok n o w na sA R N T( a r y l
hydrocarbon receptor nuclear transporter) is constitu-
tively expressed, whereas HIF-1a is induced, amongst
other stimuli, by hypoxia. During normoxia HIF-1a is
hydroxylated at specific prolyl residues leading to degra-
dation through the ubiquitin-proteasome pathway [7,8].
However, under normoxic circumstances HIF-1a can be
stabilized in cell lines and primary cell-cultures by other
stimuli, such as mechanical stress, hormones, cytokines,
growth factors but also by reactive oxygen and nitrogen
particles [9]. In ligand-induced activation of HIF-1, in
general two major phosphorylation pathways are
involved, the phosphatidylinositol-3-kinase (PI3K) and
the mitogen-activated protein kinase (MAPK) pathway
[10]. Frede et al [11] reported involvement of the ERK
(p44/42) MAPK pathway in differentiation of the human
monocytic cell line THP-1 along with increased HIF-1
activity, while increased expression of HIF-1a correlated
to differentiation was also reported by others [12].
In recent reviews the possible important role of HIF-1
in RA is extensively discussed [6,13]. Especially the pre-
sence of both hypoxia and inflammatory proteins in RA
both leading to HIF-1a stabilization and subsequent
HIF-1 activation seems to warrant an important role for
HIF-1a. Recently new small molecular drugs that have
inhibitory effect on HIF-1a have been tested in arthritis
models. Effects of 2 ME-2 (methoxyestradiol) were
investigated in a rat CIA model and in a rat AIA model
[14,15]. In the CIA model a marked suppression of
synovial gene expression of bFGF and VEGF was
observed, with parallel reduction of synovial blood ves-
sels, whereas in both CIA and AIA the severity of dis-
ease was reduced. Inhibitors of Hsp90 have been shown
to inhibit HIF-1 activity and were investigated in vitro
and in vivo in arthritis models. They showed to inhibit
paw swelling and to improve body weight. Scores for
inflammation, pannus formation, cartilage damage, and
bone resorption returned to normal [16].
Recently, involvement of another signal transduction
pathway in HIF-1 transcriptional activity was reported,
namely the Ca
2+/Calmodulin-dependent kinase II
(CaMKII) pathway [17]. Many of the cellular responses
to Ca
2+are modulated by a family of protein kinases,
namely Ca
2+/calmodulin dependent protein kinases
(CaMK), among which CaMKII is ubiquitously
expressed. CaMKII has been reported to play an
important role in osteoclast differentiation and
function [18] and to be expressed in macrophages and
fibroblasts in RA synovial tissue, and also in cultured
synovial fibroblasts (Tagashira S et al, postersession A,
no 94, ACR meeting, Washington 2006). Recently it
was shown that CaMKII activation was involved in
TLR-triggered, pro-inflammatory cytokine production
by macrophages [19].
I nt h i ss t u d yw ei n v e s t i g a t e de x p r e s s i o no fH I F - 1 a in
macrophages with subsequent activation both in an
inflammatory and hypoxic environment, and evaluated
whether this activation leads to production of proangio-
genic factors. Moreover we studied the effect of specific
signal transduction inhibitors both on HIF-1a expres-
sion and on downstream products of HIF-1 activation in
macrophages in cell-lines as well as in macrophages iso-
lated from synovial fluid (SF). We, hereby, included the
use of a novel CaMKII inhibitor, which has been shown
to have excellent efficacy in collagen-induced arthritis in
rats (Furuichi et al., abstract Fri0027, EULAR, Barcelona
2007) and which has been in phase IIb clinical trial in
Europe.
Methods
All chemicals used were from Sigma Chemical Co., St.
Louis, MO, unless otherwise indicated. RPMI 1640 med-
ium and gentamycin were purchased from Gibco (Life
Technologies Ltd, Paisley, Scotland). Fetal calf serum
(FCS) was from BioWhittaker Europe (Verviers, Bel-
gium), and culture plates from Costar (Badhoevedorp,
The Netherlands). NE-PER® Nuclear and Cytoplasmic
Extraction Reagents were obtained from Pierce Technol-
o g y( R o c k f o r d ,I L ) .A n t i -H I F - 1 a for Western Blotting
was from BD Transduction labs. (BD Biosciences, Breda,
the Netherlands); anti-HIF-1alpha 67sup (nr 463) for
immunohistochemistry was from Abcam (Cambridge,
UK). The signal transduction inhibitors LY294002,
PD98059, KN-93, and the HIF-1a inhibitor YC-1 were
purchased from Calbiochem (via Merck Eurolab,
Amsterdam, The Netherlands). SMP-114 was supplied
by Dainippon Sumitomo Pharma (Osaka, Japan). All
reagents for RNA isolation and reverse transcriptase
reaction were purchased from Invitrogen, Life Technol-
ogies (Gaithersburg, MD). Reagents for real-time RT-
PCR were obtained from Applied Biosystems (Foster
City, CA).
Cell culture of macrophages
SF was obtained from 14 patients with active RA, who
were visiting our outpatient clinic. Local research ethics
committee gave approval for the study and all patients
had given informed consent. SF was diluted 1:1 with
RPMI plus 10 mg/ml gentamicin. Subsequently mono-
nuclear cells (MC) were isolated by Lymphoprep density
gradient centrifugation. SFMCs were cultured (5 × 10
6
cells/ml) in 2 ml RPMI + 2% human pooled serum in
6-well plates (Costar, Badhoevedorp, the Netherlands)
or in 1 ml in 12-well plates at 37°C in a 5% CO2 atmo-
sphere. The cells that adhered after two hours were
used for experiments. For hypoxia experiments cells
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Invivo2 200, with an O2 level of 1%.
THP-1 monocytic cells (ATCC-LGC, Middlesex, UK)
were cultured in RPMI plus additives (25 mM HEPES,
200 nM glutamine, 100 mM Na-pyruvate, 10 mg/ml
gentamicin, 0.05 M b-mercaptoethanol, 2.2 μg/ml
amphotericin B) supplemented with 10% FCS and were
differentiated into macrophages with 100 nM PMA
(phorbol 12-myristate 13-acetate) during 3 days in
RPMI plus 10% FCS and additives. Culture or stimula-
tion periods are indicated where relevant.
HIF-1a expression in rheumatoid synovial tissue and in
THP-1 macrophages
Synovial tissue was obtained from RA patients (n = 8),
who underwent synovectomy or joint replacement sur-
gery, and who had given informed consent. Synovial tis-
sue was formalin fixed and paraffin embedded, and 4
μM slides were cut. Sections were deparaffinised with
xylene and rehydrated with ethanol and water. Endogen-
ous peroxidase activity was blocked with 0.3% hydrogen
peroxide in PBS. The sections were incubated overnight
at 4°C with monoclonal antibody HIF-1alpha67sup. For
detection, the sections were incubated with peroxidase
labeled anti-mouse polymer from EnVision Kit (K4006,
DAKO, Glostrup, Denmark). Sections were also stained
for macrophages (CD68, clone PGM-1, DAKO), and
vessels (CD31, clone JC70A, DAKO).
HIF-1a expression was detected by Western blotting
in THP-1 macrophages stimulated with 1 μg/ml LPS for
6 hours or left unstimulated. Nuclear extracts were pre-
pared with the NE-PER® Nuclear and Cytoplasmic
Extraction Reagents according to the manufacturers’
instructions. Samples were loaded onto a 10% SDS-
PAGE gel and resolved by running at 120 V and 15
Watt constant. Semidry blotting onto nitrocellulose
membrane was followed by immunodetection with
anti-HIF-1a (BD Pharmingen) and anti-mouse-immuno-
globulins labeled with HRPO. Enhanced chemilumines-
cence (ECL) detection was performed according to the
manufacturer’s guidelines (Lumi-Light
plus,R o c h e
Diagnostics).
mRNA expression of HIF-1a and VEGF
THP-1 cells (1 × 10
6/ml) were cultured in 6-well plates
and stimulated with 1 μg/ml LPS at different time
points during differentiation. After 4 hours of stimula-
tion total RNA was isolated from the cells with TRIzol
reagent according to the manufacturers’ instructions as
described earlier [20]. DNAse treatment (Ambion, Hun-
tingdon, Cambridgeshire, UK) was performed and sub-
sequently cDNA was synthesized from 2.0 μgo ft o t a l
RNA using M-MLV Reverse Transcriptase and oligo
(dT)14-18. For measurement of mRNA for HIF-1a,
VEGF, IL-8, matrix metalloproteinase (MMP)-9 and gly-
ceraldehyde-3-phosphate dehydrogenase (GAPDH) 1 μl
of cDNA in triplicate was used for amplification by the
Taqman real-time PCR system (ABI Prism 7900HT
Sequence Detection System, Applied Biosystems, Foster
City, CA) with specific Taqman primers/probes (Applied
Biosystems). Amplification was performed using stan-
dard conditions and calculations of fold induction were
performed as described earlier. The amount of target,
normalized to an endogenous reference (GAPDH) and
relative to the unstimulated control sample, is given by:
2
-ΔΔCT.m R N Ae x p r e s s i o ni nS F Mw a sd e t e r m i n e di n
the same way.
Determination of VEGF, IL-8, and MMP-9 levels in cell
culture supernatants
Production of pro-angiogenic factors was measured
in cell culture supernatants of THP-1 cells (0.5 × 10
6/
0.5 ml in 24 well plates) during differentiation either
unstimulated or stimulated for 48 hours with 1 μg/ml
LPS. Effects of YC-1, a specific HIF-1a inhibitor, and of
kinase inhibitors (30 minutes pre-treatment) on protein
production was also measured in macrophage cell
supernatants after 48 hours LPS stimulation.
VEGF, IL-8, and MMP-9 levels were measured in cell
supernatants by ELISA, using matched antibody pairs
for ELISA and recombinant proteins as standards (R&D
Systems). For optimal determination of MMP-9,
precoating with F(ab)2 fragments of goat-anti-mouse
IgG-Fc (Jackson, West Grove, Pennsylvania, USA) in
0.1 M carbonate buffer (pH = 9.6) for at least 48 hours
was done before coating of the capturing antibody.
In all ELISAs, after sample incubation and binding
of the biotinylated detecting antibodies, color reaction
was performed with streptavidin-poly-HRP (Sanquin,
Amsterdam, the Netherlands) and tetramethyl-benzidin
(TMB, Roth, Karlsruhe, Germany).
Statistics
One-way ANOVA with Dunnett’s post test was per-
formed using GraphPad Prism version 4.00 for Win-
dows, GraphPad Software (San Diego, California, USA).
Results
HIF-1a expression in rheumatoid synovial tissue
First we investigated expression of HIF-1a in RA syno-
vial tissue. Following the staining procedure described
by Zhong and Semenza [21] and using monoclonal anti-
body HIF-1alpha67sup we detected a nuclear staining of
HIF-1a in synovial tissues from all RA patients, which
was not restricted to the lining layer but had a diffuse
pattern throughout the tissue (figure 1A and 1D, see
arrows) [22]. Staining of synovial tissue of OA patients
showed significantly less HIF-1a staining (data not
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staining for macrophages (CD68) (figure 1B) and vessels
(CD31) (figure 1C).
mRNA expression of HIF-1a and VEGF in THP-1 cells and
synovial macrophages
To investigate both mRNA and protein expression of
HIF-1a in vitro we first measured levels of HIF-1a and
VEGF mRNA in differentiated THP-1 cells and in
macrophages from SF (n = 4) with realtime RTPCR. In
figure 2 it is shown that HIF-1a mRNA expression is
increased in THP-1 cells, and that macrophages isolated
from RA SF have very high HIF-1a expression (mean
fold induction of 7.9). VEGF mRNA levels were also
increased in SF macrophages (mean fold induction of
5.2). IL-8 mRNA levels were increased 40-50 fold in
both THP-1 and SF macrophages, and MMP-9 mRNA
levels were two-fold higher in SF macrophages. Incuba-
tion of SF macrophages in an hypoxia incubator did not
increase HIF-1a expression further, but did raise VEGF
mRNA levels slightly (figure 3).
HIF-1a protein expression is induced during
differentiation under non-hypoxic conditions and can be
blocked by kinase inhibitors
Next we continued with protein expression of HIF-1a
during differentiation and after stimulation. THP-1 cells
under non-hypoxic conditions were induced to differen-
tiation with 100 nM PMA and HIF-1a expression was
studied in LPS stimulated or unstimulated cells at sev-
eral time points (figure 4A). We observed an increased
HIF-1a expression during differentiation in unstimu-
lated cells, which was even higher after LPS stimulation.
Then we investigated the effects of the specific MEK
inhibitor PD98059, the PI3K inhibitor LY294002, and
the CAMKII inhibitor KN93 on HIF-1a protein expres-
sion in differentiated THP-1 cells. Figure 4B shows that
the MEK inhibitor PD has an inhibitory effect at 50 μM
AB
CD
Figure 1 Expression of HIF-1a, CD68, and CD31 in RA synovial tissue. Representative pictures of immunohistochemical staining of RA
synovial tissue obtained after total joint replacement. Consecutive (A, B, C) sections were treated according to standard procedures for immuno-
histochemistry, and stained for HIF-1a (A, D), macrophage marker CD68 (B), and endothelial cell marker CD31 (C). Magnification A-C 200×, D
400×.
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Figure 2 mRNA expression of HIF-1a, VEGF, IL-8, and MMP-9 in macrophages under normoxia.H I F - 1 a, VEGF, IL-8 and MMP-9 mRNA
levels under normoxia from differentiated THP-1 cells (macrophages) and macrophages isolated from RA synovial fluid with LPS stimulation (4
hours) and without LPS stimulation. mRNA expression was expressed as fold induction (2
-ΔΔCt, Ct is threshold value), which is normalized to a
household gene (GAPDH) and relative to an unstimulated sample (fold induction = 1).
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Figure 3 mRNA expression of HIF-1a and VEGF in RA SF macrophages under normoxia and hypoxia. HIF-1a and VEGF mRNA levels of
synovial fluid macrophages (n = 4) under normoxic or hypoxic (1% O2) conditions with and without LPS stimulation. mRNA expression was
expressed as fold induction (2
-ΔΔCt, Ct is threshold value), which is normalized to a household gene (GAPDH) and relative to an unstimulated
sample (fold induction = 1).
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PI3K inhibitor LY at 10 and 50 μM, and the CaMKII
inhibitor KN at 10 μM. So these various signal transduc-
tion pathways are involved in LPS-induced HIF-1a
expression in macrophages.
Production of proangiogenic factors during
differentiation of THP-1 cells
To see whether differentiation of THP-1 cells leads to
increased production of pro-angiogenic factors, VEGF,
IL-8 and MMP-9, protein levels were measured in cell
supernatants of stimulated and unstimulated cells after
0 ,1 ,2a n d3d a y so fd i f f e r e n t i a t i o n .A sc a nb es e e ni n
figure 5A protein production of VEGF, MMP-9 and IL-
8 increased during differentiation. Preincubation with
the specific HIF-1a blocker YC-1 significantly inhibited
VEGF-, IL-8- and MMP-9 production in THP-1 macro-
phages (figure 5B). From these results we can conclude
that production of these angiogenic factors in macro-
phages is regulated by activation of HIF-1a.
Regulation of VEGF, IL-8 and MMP-9 production
To determine which intracellular pathways are involved
in production of these angiogenic factors THP-1 cells
were incubated with specific inhibitors of the ERK-,
PI3K-, and CaMKII pathways. Since we had found effects
of the CaMKII inhibitor KN-93 on HIF-1a expression we
decided to include the novel CaMKII inhibitor SMP-114
(in phase 2 clinical trial for treatment of RA). Significant
inhibition of VEGF production was seen with 10 μMP D ,
LY and KN, but also with 3 and 10 μMS M P - 1 1 4( f i g u r e
6). KN-93 at concentration 2 μM did not inhibit VEGF
production in contrast to SMP-114 at 3 μM. From pre-
vious unpublished research we know that SMP-114 can
also be used at higher concentrations (30 μM) than KN-
93 without becoming cytotoxic. IL-8 production was sig-
nificantly inhibited by CaMKII inhibitors (KN-93 at
10 μMa n dS M P - 1 1 4a t3 0μM). MMP-9 production was
slightly increased by LPS stimulation, but decreased by
PI3kinase and CaMKII inhibitors (not significant).
We then performed these studies in SF macrophages.
Figure 7 shows that VEGF production in SF macro-
phages was significantly reduced by the PI3K-inhibitor
and the CaMKII inhibitor SMP-114. SMP-114 can be
safely used at this concentration, whereas KN-93 can
not. IL-8 production was not affected by signal trans-
duction inhibitors (data not shown). As stimulation of
SF macrophages with LPS reduced the high constitutive
production of MMP-9, inhibitors were also added to
unstimulated cells. MMP-9 production was inhibited by
PI3K and CaMKII inhibitors, but this did not reach sta-
tistical significance (data not shown).
Since we detected an increase in VEGF mRNA expres-
sion in SF macrophages that were incubated in an
Figure 4 HIF-1a protein expression in THP-1 monocytes and macrophages. Protein expression of HIF-1a measured by Western Blotting in
nuclear extracts of THP-1 cells. (A) HIF-1a expression during differentiation of THP-1 monocytes to macrophages in unstimulated and LPS-
stimulated cells (6 hours). (B) Effect of different concentrations (2,10 or 50 μM) of kinase inhibitors on HIF-1a expression in LPS-stimulated THP-1
macrophages (cells were differentiated for 72 hours with 100 nM PMA): PD = PD98059-MEK inhibitor, LY = LY294002-PI3K inhibitor, KN = KN93-
CAMKII inhibitor.
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sured under these circumstances. Figure 8 shows that
VEGF and MMP-9 production did not increase when
macrophages were stimulated with LPS in an hypoxia
incubator compared to a normoxic incubator. However,
PI3K and CaMKII inhibitors reduced VEGF levels as
was seen under normoxia. Levels of IL-8 highly
increased when the cells were incubated in hypoxia, and
significant reduction was achieved with PI3K- and CaM-
KII inhibitors.
Discussion
In this study we showed that HIF-1a is expressed in
synovial tissue from rheumatoid arthritis patients, and
also in macrophages isolated from RA SF. In the inflam-
matory, non-hypoxic regulation of HIF-1a expression
both PI3kinase and CaMKII pathways are involved,
which is reflected by significant reduction in VEGF
levels by specific inhibitors.
Expression of HIF-1a, the inducible part of the tran-
scription factor HIF-1, has been described for RA syno-
vial tissue [23,24] especially in macrophages in the
synovium [25]. However contradicting results have been
reported demonstrating either nuclear or cytoplasmic
staining, and with or without differences between RA
and OA synovial tissue [23-25]. In the field of oncology,
in which many publications report HIF-1a staining, the
procedure as described by Semenza’sg r o u pi sc o n s i d -
ered the standard staining [21]. They described in differ-
ent tissues a nuclear staining of HIF-1a,m o s t l yw i t ha
diffuse pattern or located near necrotic areas or neovas-
cular areas. We followed these staining procedures and
found nuclear staining in 8 synovial specimens, both in
the lining and in the sublining layer. Although we did
not perform double staining it is likely that HIF-1a was
expressed mainly by macrophages since these cells are
found everywhere in the tissue. In contrast to one study
[23] but in accordance with others [25], we found minor
HIF-1a expression in OA synovial tissue [22]. This is in
line with the nature of the tissue being inflammatory
and angiogenic in RA, and less inflammatory in osteoar-
thritis synovial tissue.
Stabilization of HIF-1a can take place under hypoxic
conditions but can also be induced by differentiation of
monocytes to macrophages and by stimulation with LPS
[11,12]. Macrophages isolated from RA SF come from
an hypoxic environment [3], which was reflected by
their high HIF-1a and VEGF mRNA levels compared to
macrophages derived from THP-1 cells. Incubating
these cells in an hypoxia incubator did not increase
HIF-1a expression further since these cells already were
hypoxic. By Western blotting we demonstrated that
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day0 day1 day2 day  3
0
500
1000
1500
2000
2500
V
E
G
F
 
(
p
g
/
m
l
)
MMP-9
day 0 day 1 day 2 day3
0
500
1000
1500
2000
2500
3000
n
g
/
m
l
IL-8
d a y  0d a y  1d a y  2d a y  3
0
100
200
250
500
750
1000
1250
n
g
/
m
l
A
VEGF
- 0 1 10
0
250
500
750
1000
1250
1500
**
**
LPS+μ μ μ μM YC-1
(
p
g
/
m
l
)
MMP-9
- 0 1 10
0
250
500
750
1000
1250
μ μ μ μM YC-1
(
n
g
/
m
l
)
** **
IL-8
- 0 1 10
0
250
500
750
**
*
μ μ μ μM YC-1
(
n
g
/
m
l
)
B
Figure 5 Protein (VEGF, IL-8, and MMP-9) production of THP-1 cells during differentiation. (A). THP-1 monocytic cells (n = 3) were
differentiated for 3 days and were stimulated with LPS for 48 hours (hatched bars) or left unstimulated (open bars). Protein production of VEGF,
IL-8 and MMP-9 was measured in cell supernatants by ELISA. In (B) the HIF-1a specific inhibitor YC-1 was added to the cultures (n = 3) and
significant inhibition was seen for all proteins. Significance of inhibition was calculated compared to LPS stimulated sample (no inhibitor) with
one-way ANOVA with Dunnett’s post test: * p < 0.05, ** p < 0.01.
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Page 7 of 11HIF-1a protein expression can be inhibited by the
PI3kinase inhibitor and the CaMKII inhibitor KN93 at
10 μM in THP-1 macrophages, so there is a role for
CaMKII signalling in HIF-1 regulation.
Induction of HIF-1a expression leads to production of
angiogenic proteins. Both VEGF and MMP-9 levels
increased during differentiation without stimulation with
LPS, and this was further increased following
stimulation. IL-8 production was also induced but highly
increased after stimulation with LPS. When we used
YC-1, (3-(5’-hydroxymethyl-2’-furyl)-1-benzyl indazole),
which is considered a specific HIF-1a inhibitor) [26,27],
levels of VEGF and MMP-9 were completely reduced
whereas IL-8 levels were less diminished. This implies
that VEGF and MMP-9 production are under control of
HIF-1, whereas this is partly the case for IL-8. It has
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Figure 6 Kinase inhibitor effects on VEGF, IL-8, and MMP-9 production by THP1 macrophages (n = 4). Differentiated THP-1 cells were
stimulated for 48 hours with LPS and pretreated with different concentrations of inhibitors of ERK, PI3K, and CAMKII pathways. PD = PD98059-
MEK inhibitor, LY = LY294002-PI3K inhibitor, KN = KN93-CaMKII inhibitor, SM = SMP114-CaMKII inhibitor. Significance of inhibition was calculated
compared to LPS stimulated sample with one-way ANOVA with Dunnett’s post test: * p < 0.05, ** p < 0.01.
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Page 8 of 11been reported that YC-1 can induce apoptosis in vitro in
cell-lines, but this is primarily at concentration higher
than 5 μM, so the reduction that was seen at 1 μMi s
due to blocking of HIF-1 activity [28].
Incubating THP-1 macrophages with different concen-
trations of the signal transduction inhibitors gave a sig-
nificant reduction of VEGF protein levels at 10 μMo r
lower concentrations for all inhibitors, but for SF
macrophages this was only the case for the PI3kinase
i n h i b i t o ra n df o rS M P - 1 1 4 .T here is often a difference
between cell lines and primary cell cultures, but the
data convincingly show that these pathways are crucial
in HIF-1 induced VEGF production. Incubation of SF
macrophages in an hypoxia incubator did not increase
VEGF or MMP-9 protein production, while IL-8 pro-
duction was increased. Apparently hypoxia and LPS
work synergistically in induction of IL-8, which still can
be inhibited by PI3K- and CaMKII inhibitors. MMP-9
levels were decreased in SFM after stimulation with
LPS. Lee et al. [29] showed that in serum of conditioned
media inhibitory factors are present that inhibit MMP-9
production by macrophages. Since we cultured SFM in
RPMI supplemented with 2% human pooled serum, it
could well be that this is the reason for suppression of
MMP-9 production.
Recently it was reported that in the mouse macrophage
cell line RAW264.7 LPS induced activation was enhanced
by hypoxia, resulting in increased TNF-a secretion [30].
Also, Fang et al. showed that HIF-1 and HIF-2 are impor-
tant transcriptional effectors in primary macrophages
experiencing hypoxia, more important than NF-B [31].
In another recent publication it was shown that LPS
induces intracellular calcium release in macrophages and
that CaMKII is activated after LPS-induced TLR-activation
[19]. It was demonstrated that CaMKII activation directly
induces cytokine production in macrophages. From these
studies is clear that both hypoxia and inflammation are
important in macrophage activation and that different sig-
nal transduction pathways are involved.
In this study we confirm the involvement of the PI3ki-
nase pathway in HIF-1a regulation in THP-1 macro-
phages and macrophages from RA SF. We suspected a
role for CaMKII inhibition initially based on a report by
Yuan et al., in which they mentioned that HIF-1 tran-
scriptional activity was dependent on CaMKII activation
[17]. In our study we found that CaMKII inhibition
reduces HIF-1a expression and VEGF production in sti-
mulated macrophages. In inflammatory conditions such
as RA the relevance of HIF-1 primarily lies in control-
ling angiogenesis, since this is an important feature of
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Figure 7 P r o t e i np r o d u c t i o ni nc e l ls u p ernatants of RA SF macrophages. Cells were stimulated with LPS and pretreated with different
concentrations of inhibitors of ERK, PI3K, and CAMKII pathways. Protein production was measured in cell supernatants by ELISA. (A) VEGF
production by SF macrophages (SFM) (n = 6). PD = PD98059-MEK inhibitor, LY = LY294002-PI3K inhibitor, KN = KN93-CaMKII inhibitor, SM =
SMP114-CaMKII inhibitor. Significance of inhibition was calculated compared to LPS stimulated sample with one-way ANOVA with Dunnett’s post
test: * p < 0.05, ** p < 0.01.
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Page 9 of 11RA. Inhibition of angiogenesis has already been investi-
gated in a number of animal arthritis studies, via drug
intervention [15], or by gene therapy [32] in rat models
of arthritis. In the introduction we already mentioned
animal studies with specific HIF-1 inhibitors. In humans
anti-angiogenic effects are known for some drugs, for
instance anti-TNF therapy induced reduction of VEGF
levels in RA patients [33]. Anti-angiogenic effects are in
our study now established for the CaMKII inhibitor
SMP-114 in macrophages. However, this is clearly an
off-target effect and although beneficial in this case
effects like these need further investigation in new
developed drugs.
Conclusions
In this study we demonstrated inhibition of HIF-1a pro-
tein expression and significant inhibition of VEGF pro-
duction by CaMKII inhibitors. This is an unknown but
very interesting effect of the CaMKII inhibitor SMP-114,
which is now in clinical trial as DMARD for the
treatment of rheumatoid arthritis. This effect may con-
tribute to the anti-arthritic effects of SMP-114.
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